Lipid peroxidation in hemodialysis patients: Effect of vitamin C supplementation

Clinical Biochemistry

Volumn 41, Issue 6, 2008, Pages 381-386

  Ferretti, Gianna ^a   Bacchetti, Tiziana ^a   Masciangelo, Simona ^a   Pallotta, Giosafatte ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Ospedale Umberto I   (Italy)

Author keywords

AGE adducts; C reactive protein (CRP); Hemodialysis patients; High density lipoproteins (HDL); Inflammation; Lipid peroxidation; Paraoxonase (PON1); Reactive oxygen species (ROS); Renal disease

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ARYLDIALKYLPHOSPHATASE 1; ASCORBIC ACID; LIPID HYDROPEROXIDE;

ADULT; AGED; ARTICLE; ATHEROGENESIS; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PATIENT MONITORING; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION;

AGED; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ASCORBIC ACID; DIETARY SUPPLEMENTS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; LIPID PEROXIDATION; LIPID PEROXIDES; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS;

EID: 40849114570     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.12.011     Document Type: Article

References (40)

1. Stenvinkel P., Pecoits-Filho R., and Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 14 (2003) 1927-1939
2. Brown J.H., Hunt L.P., Vites N.P., et al. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 9 (1994) 1136-1142
3. Kaysen G.A., and Eiserich J.P. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 15 (2004) 538-548
4. Pawlak K., Pawlak D., and Mysliwiec M. Impaired renal function and duration of dialysis therapy are associated with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease. Clin Biochem 40 (2007) 81-85
5. Nguyen-Khoa T., Massy Z.A., De Bandt J.P., et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 16 (2001) 335-340
6. Ward R.A., and McLeish K.R. Oxidant stress in hemodialysis patients: what are the determining factors?. Artif Organs 27 (2003) 230-236
7. Bakaev V.V., Efremov A.V., and Tityaev I.I. Low levels of dehydroascorbic acid in uraemic serum and the partial correction of dehydroascorbic acid deficiency by haemodialysis. Nephrol Dial Transplant 14 (1999) 1472-1474
8. Paul J.L., Sall N.D., Soni T., et al. Lipid peroxidation abnormalities in hemodialyzed patients. Nephron 64 (1993) 106-109
9. Schiavon R., De Fanti E., Giavarina D., et al. Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 247 (1996) 71-80
10. Gugliucci A., Mehlhaff K., Kinugasa E., et al. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clin Chim Acta 377 (2006) 213-220
11. Juretic D., Tadijanovic M., Rekic B., et al. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Croat Med J 42 (2001) 146-150
12. Beltowski J. Protein homocysteinylation: a new mechanism of atherogenesis?. Postepy Hig Med Dosw 59 (2005) 392-404
13. Mackness B., Quarck R., Verreth W., et al. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 26 (2006) 1545-1550
14. Aviram M., and Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 16 (2005) 393-399
15. Ferretti G., Bacchetti T., Busni D., et al. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab 89 (2004) 2957-2962
16. Ferretti G., Bacchetti T., Marotti E., et al. Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity. Metabolism 52 (2003) 146-151
17. Ferretti G., Bacchetti T., Marchionni C., et al. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 38 (2001) 163-169
18. Tarng D.C., Liu T.Y., and Huang T.P. Protective effect of vitamin C on 8-hydroxy-2'-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients. Kidney Int 66 (2004) 820-831
19. Chan D., Irish A., Croft K.D., et al. Effect of ascorbic acid supplementation on plasma isoprostanes in haemodialysis patients. Nephrol Dial Transplant 21 1 (2006) 234-235
20. Fumeron C., Nguyen-Khoa T., Saltiel C., et al. Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. Nephrol Dial Transplant 20 (2005) 1874-1879
21. Ferretti G., Bacchetti T., Principi F., et al. Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult Scler 11 6 (2005) 677-682
22. Nourooz-Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol 300 (1999) 58-62
23. Friedman A.N., Bostom A.G., Selhub J., et al. The kidney and homocysteine metabolism. J Am Soc Nephrol 12 (2001) 2181-2189
24. Sutherland W.H., de Jong S.A., and Walker R.J. Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: an in vitro study. Nephrol Dial Transplant 19 (2004) 75-82
25. Suehiro T., Ikeda Y., Shiinoki T., et al. Serum paraoxonase (PON1) concentration in patients undergoing hemodialysis. J Atheroscler Thromb 9 (2002) 133-138
26. Morena M., Cristol J.P., Dantoine T., et al. Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients. Nephrol Dial Transplant 15 (2000) 389-395
27. Biasioli S., Schiavon R., Petrosino L., et al. Paraoxonase activity and paraoxonase 1 gene polymorphism in patients with uremia. ASAIO J 49 (2003) 295-299
28. Aviram M., Rosenblat M., Billecke S., et al. Human serum paraoxonase (PON1) is inactivated by oxidized low-density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26 (1999) 892-904
29. Gugliucci A., Lunceford N., Kinugasa E., et al. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients. Clin Chim Acta 384 (2007) 105-112
30. Josse D., Lockridge O., Xie W., et al. The active site of human paraoxonase (PON1). J Appl Toxicol 21 (2001) S7-S11
31. Bowry V.W., Stanley K.K., and Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A 89 21 (1992) 10316-10320
32. James R.W., and Deakin S.P. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 37 (2004) 1986-1994
33. Jaouad L., Milochevitch C., and Khalil. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic Res 37 (2003) 77-83
34. Girndt M., Köhler H., Schiedhelm-Weick E., et al. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 47 (1995) 559-565
35. Kumon Y., Suehiro T., Ikeda Y., et al. Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6. Life Sci 73 (2003) 2807-2815
36. Frei B., England L., and Ames B.N. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci U S A 86 (1989) 6377-6381
37. Jarvik G.P., Tsai N.T., McKinstry L.A., et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 22 (2002) 1329-1333
38. Calla M.S., and Lynch S.M. Vitamin C preserves the cardio-protective paraoxonase activity of high-density lipoprotein during oxidant stress. Arch Biochem Biophys 452 (2006) 129-137
39. Costa L.G., Vitalone A., Cole T.B., et al. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69 (2005) 541-550
40. Ikeda Y., Suehiro T., Itahara T., et al. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol 67 (2007) 358-365